Novo Nordisk's Q1 profit beats forecasts
Tweet
Share
E-mail
FILE PHOTO: The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, February 4, 2026. REUTERS/Tom Little/File Photo
COPENHAGEN, May 6 (Reuters) - Novo Nordisk, the maker of weight-loss drug Wegovy, on Wednesday reported a first-quarter adjusted operating profit above expectations.
The Danish drugmaker is banking on demand for its new weight-loss pill as competition with U.S. rival Eli Lilly intensifies and investors demand proof that fast-rising volumes can offset a bruising obesity drug price war.
(Reporting by Stine Jacobsen, editing by Terje Solsvik)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ukrainian capital Kyiv under attack by Russian ballistic missiles, mayor says
- Lebanon hands Assad-era general to Syria in first such transfer since Assad’s fall
- US appeals court upholds big real estate settlement despite class members' objections
Create E-mail Alert Related Categories
ReutersSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
